Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuneering Corporation filings document the disclosure record of a late-stage clinical oncology company developing Deep Cyclic Inhibitors for cancer. Recent Form 8-K reports cover operating and financial results, R&D spending, capital resources, and clinical updates for atebimetinib (IMM-1-104), including its evaluation with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
Proxy materials describe annual meeting matters for holders of Class A common stock, including director elections, auditor ratification, board governance and voting procedures. The filing record also includes material-event disclosures addressing material agreements, capital-structure matters, shareholder votes, and regulatory and clinical disclosures for the company’s oncology development programs.
Immuneering Corp reported that BlackRock, Inc., a Delaware corporation, beneficially owns 4,356,235 shares of Immuneering’s Class A stock, representing 6.7% of the class as of June 30, 2026. BlackRock has sole voting power over 4,314,766 shares and sole dispositive power over 4,356,235 shares, with no shared voting or dispositive power.
Various underlying clients and other persons have rights to dividends or sale proceeds related to these shares, but no individual person holds more than 5% of Immuneering’s outstanding common shares through these interests.
Immuneering Corp granted Chief Financial Officer Andrew Gengos stock options covering 650,000 shares of Class A Common Stock at an exercise price of $4.78 per share, expiring July 16, 2036. The options vest monthly over four years under a detailed, step-up vesting schedule tied to continued employment.
Immuneering Corp executive Andrew Gengos, Chief Financial Officer, reports ownership of 225,000 shares of Class A Common Stock, held directly. This disclosure outlines his reported equity stake as an officer and does not list any open-market transactions or derivative positions.
Immuneering Corp director and CEO Benjamin J. Zeskind reported buying 2,400 shares of Class A Common Stock in an open-market purchase on June 23, 2026 at a weighted average price of $4.5617 per share, with individual trade prices ranging from $4.55 to $4.59 through a broker-dealer.
After this transaction, he directly owns 2,315,252 shares of Immuneering’s Class A Common Stock. A separate entry shows 894,927 shares held indirectly by the Benjamin J. Zeskind 2020 Family Trust, where his spouse Lisa Schwartz serves as sole trustee.
Immuneering Corp's Chief Scientific Officer Brett Matthew Hall reported an open-market purchase of Class A Common Stock. On June 15, 2026, he bought 6,035 shares at a weighted average price of $4.15 per share. Following this transaction, he directly owns 382,531 shares of Immuneering Corp stock. The filing notes the trade was executed through a broker-dealer in multiple transactions at prices ranging from $4.146 to $4.15 per share, with the reported price representing the weighted average.
Immuneering Corporation is appointing Andrew Gengos as Chief Financial Officer, Treasurer and principal financial officer, effective when he starts work, expected on or before July 16, 2026. Current Senior Vice President Finance and Chief Accounting Officer Mallory Morales will remain the company’s principal accounting officer.
Gengos will receive an annual base salary of $530,000 and be eligible for a target annual bonus equal to 40% of base salary, based on Board-set objectives. As a material inducement to join, he is expected to receive an option to purchase 650,000 shares of common stock under the 2025 Employment Inducement Award Plan, contingent on his start date.
If terminated without cause or he resigns for good reason, he is eligible for 12 months of base salary continuation, any earned prior-year bonus, and up to 12 months of subsidized COBRA. After a qualifying change in control, he may instead receive similar salary and COBRA benefits, an additional payment equal to 1.0x his target bonus, and accelerated vesting of specified equity awards.
Immuneering Corp director Thomas J. Schall received a grant of stock options covering 33,350 shares of Class A common stock at an exercise price of $4.12 per share. The options vest in equal monthly installments over one year starting on July 11, 2026.
The award will be fully vested by June 11, 2027 or on the date of the 2027 annual meeting of stockholders, whichever occurs first. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Immuneering Corp director Diana Hausman received a grant of stock options covering 33,350 shares of Class A common stock. The options have an exercise price of $4.12 per share and were awarded as compensation, not purchased in the market.
The option grant vests in equal monthly installments over one year starting on July 11, 2026, and will be fully vested by June 11, 2027 or the date of the 2027 annual meeting of stockholders, whichever occurs first. After this grant, she holds options for 33,350 shares directly.
Immuneering Corp director Robert J. Carpenter received a grant of stock options for 33,350 shares of Class A common stock. The options have an exercise price of $4.12 per share and expire on June 11, 2036. They vest in equal monthly installments over one year starting July 11, 2026, becoming fully vested by June 11, 2027 or the 2027 annual stockholder meeting, whichever occurs first. Following this grant, he holds 33,350 stock options directly.
Immuneering Corp director Laurie Keating received a grant of 33,350 stock options. These options allow her to buy Class A common stock at an exercise price of $4.12 per share and are held directly.
The options vest in equal monthly installments over one year starting on July 11, 2026. They will be fully vested and exercisable on June 11, 2027, or on the date of the 2027 annual meeting of stockholders, whichever occurs first. After this grant, Keating holds 33,350 stock options in total.